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1  |  INTRODUC TION
Prostate cancer (PCa) is the most common male cancer, affecting 
approximately 1.3 million men worldwide (Bray et al., 2018). In the 
UK, more than 48,000 new PCa cases were registered in 2015– 
2017, with prevalence being highest in men aged 75 to 79 years, 
and this is predicted to rise by 12% by 2030 (CancerResearchUK, 
2015– 17). Older men with PCa, defined as those men 70 years of 
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The purpose of this study was to compare fitness parameters and cardiovascular 
disease risk of older and younger men with prostate cancer (PCa) and explore how 
men's fitness scores compared to normative age values. 83 men were recruited post- 
treatment and undertook a cardiopulmonary exercise test (CPET), sit- to- stand, step- 
and-	grip	strength	tests	and	provided	blood	samples	for	serum	lipids	and	HbA1c.	We	
calculated waist- to- hip ratio, cardiovascular risk (QRISK2), Charlson comorbidity index 
(CCI)	and	Godin	leisure-	time	exercise	questionnaire	[GLTEQ].	Age-	group	comparisons	
were	made	using	normative	data.	Men	>	75	years,	 had	 lower	 cardiopulmonary	 fit-
ness, as measured by VO2 Peak (ml/kg/min) 15.8 + 3.8 p < 0.001, and lower grip 
strength(28.6+5.2 kg p	<	0.001)	than	younger	men.	BMI	≥30kg/m2 and higher blood 
pressure all contributed to a QRisk2 score indicative of 20% chance of cardiovascu-
lar risk within 10 years (mean: 36.9– 6.1) p	<	0.001.	Age,	BMI	and	perceived	physical	
activity	were	significantly	associated	with	lower	cardiopulmonary	fitness.	Men	with	
PCa	>	75	years	had	more	cardiovascular	risk	factors	compared	to	normative	standards	
for	men	of	 their	age.	Although	ADT	was	more	 frequent	 in	older	men,	 this	was	not	
found to be associated with cardiopulmonary fitness, but obesity and low levels of 
physical activity were. Secondary prevention should be addressed in men with PCa to 
improve men's overall health.
K E Y W O R D S
cardiopulmonary fitness, cardiovascular risk, obesity, older person, prostatic neoplasm, 
secondary prevention
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age and older (Boyle et al., 2019), have been reported to have less 
favourable outcomes in observational studies, possibly due to later 
diagnosis, conservative treatment and adverse effects of treat-
ment (Bechis et al., 2011; Pettersson et al., 2018; Vernooij et al., 
2019;	Yang	et	al.,	2017).	As	life	expectancy	increases,	we	are	likely	
to see the burden of PCa cancer in older men increase and need 
to	consider	 their	complex	health	needs	 (Droz	et	al.,	2014;	WHO,	
2018). Older men with PCa are more likely to have comorbidities, 
with more than 30% of men diagnosed having one or more co- 
existing chronic illnesses (Roy et al., 2018). Diabetes, cardiovascu-
lar disease (CVD) and hypertension can impact on PCa treatment 
decisions and treatment- related adverse effects (Bradley et al., 
2014;	Søgaard	et	al.,	2013).	Men	over	70	are	also	more	likely	to	be	
treated	conservatively	with	androgen	deprivation	 therapy	 (ADT),	
which may have adverse consequences for their physical and psy-
chological health (Bourke et al., 2013).
Studies have shown an association between all- cause mortality 
and	ADT	in	men	with	PCa	(Davis	et	al.,	2015;	Keating	et	al.,	2013;	
O'Farrell	 et	 al.,	 2015).	While	 ADT	 is	 highly	 effective	 as	 a	 compo-
nent of combined modality therapy, its use, and specifically, the use 
of gonadotrophin- releasing hormone (GnRH) agonists, has been 
associated with the development of sarcopenic obesity and car-
diometabolic risk factors, including dyslipidaemia, insulin resistance 
and	elements	 of	metabolic	 syndrome	 (Collier	 et	 al.,	 2011;	Morote	
et	al.,	2015;	Turner	et	al.,	2017).	An	association	between	ADT	and	
increased risk of CVD and mortality has been recognised in multiple 
studies	(Bosco	et	al.,	2014;	Nguyen	et	al.,	2011;	Weaver	et	al.,	2013;	
Zhao et al., 2014) but CVD and links with increased mortality remain 
contentious in clinical practice. One possible reason for this, is that 
the outcomes of observational studies have not been confirmed in 
clinical	trials	of	PCa	treatment,	including	those	with	ADT	(Scailteux	
et al., 2017). Clinical trials have often excluded men 65 years or older 
and those with pre- existing cardiometabolic risk factors, which may 
increase	 their	 susceptibility	 to	 the	 adverse	 effects	 of	 ADT,	 and	
have been more focused on younger, healthier patient populations, 
in comparison with observational studies (Hutchins et al., 1999; 
Kennedy-	Martin	et	al.,	2015;	Thompson	et	al.,	2017).
Regarding	adverse	effects	associated	with	ADT,	there	is	a	grow-
ing body of evidence that lifestyle interventions (exercise and di-
etary advice) have significant potential for secondary prevention to 
reduce treatment- related cardiovascular risk (Gardner et al., 2014; 
Owen	et	al.,	2017;	Redig	&	Munshi,	2010;	Wall,	2016)	and	all-	cause	
mortality (Dickerman et al., 2019). Exercise and nutritional inter-
ventions have also been shown to counteract sarcopenic obesity 
(Trouwborst et al., 2018) in the non- cancer population so have po-
tential for use in men with PCa to reduce obesity, risk of diabetes 
and cardiovascular disease.
The aim of this study was to compare the fitness and CVD risk 
of older and younger patient's with PCa with the hypothesis being 
that older men with PCa have lower fitness and higher CVD risk 
compared to younger men with PCa. Thereby raising the profile of 
the importance of lifestyle interventions for secondary prevention 
in this population.
2  |  METHODS
2.1  |  Study design and recruitment
A	 cross-	sectional	 study	 design	 was	 undertaken	 with	 patients	 re-
cruited from two UK cancer centres (Surrey and Newcastle). This 
study	was	approved	by	NHS	Health	Research	Authority	(REC	Ref14/
LO/0495)	data	was	collected	from	23/7/2014	to	31/7/2015.	All	par-
ticipant's provided informed written consent. Physical and health as-
sessments were carried out in clinical and laboratory settings.
2.2  |  Study population
Men	were	 eligible	 to	 take	 part	 in	 the	 study	 if	 they	 were	 treated	
3–	36	months	post-	diagnosis,	with	stable	PSA,	<0.4ng/ml	for	surgi-
cal and radiotherapy patients <10ng/ml and androgen deprivation 
therapy	(ADT).	Men	were	recruited	if	they	had	one	or	more	of	three	
risk	factors;	BMI	<18.5	or	>25	Kg/m2; elevated blood pressure and 
or	 receiving	 ADT.	 We	 purposely	 recruited	 men	 at	 higher	 risk	 of	
chronic health problems as these men were potentially more in need 
of	secondary	prevention.	Men	were	excluded	if	they	had	a	history	
of myocardial infarction or pulmonary disease or were receiving ac-
tive	treatment	(except	ADT).	Adverse	risk	from	engaging	in	physical	
activity was assessed during a prior medical check using the Physical 
Activity	Readiness	Questionnaire	(Adams,	1999)	and	those	individu-
als deemed ‘at risk’ were excluded from the cardiopulmonary fitness 
assessment	but	were	still	included	in	the	study.	A	study	population	
and strobe diagram are presented in Figure 1.
2.3  |  Data collection
Demographic data including age, ethnicity, employment and smok-
ing status were obtained using a demographics questionnaire, com-
pleted at the start of assessment. Cancer treatment and Charlson 
Comorbidity Index (CCI) (Charlson et al., 1987) were obtained 
from medical records and reviewed by a medical practitioner. Self- 
perceived physical activity levels were measured prior to assess-
ment	by	the	Godin	Leisure	Time	Exercise	Questionnaire	(Amireault	
et al., 2015) this contains 3 core items regarding the frequency of 
strenuous, moderate and mild physical activity in periods of 15 min-
utes or more during a 7- day period. The scores are multiplied by 
weight and summed into an overall score that ranges between 0 and 
119	metabolic	equivalents	of	task	(METs)/	minutes	of	physical	activ-
ity per week.
2.4  |  Cardiovascular and metabolic assessments
Blood	pressure,	weight,	body	mass	index	(BMI),	waist	and	hip	circum-
ference were assessed. Nonfasted blood samples were evaluated for 
HbA1c,	serum	cholesterol	(total,	HDL,	LDL)	and	triglycerides.	HbA1c	
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was measured by a commercially available enzyme- linked immuno-
sorbent	 assay	 (ELISA).	 Similarly,	 serum	 cholesterol	 and	 triglycerides	
were measured by commercially available enzymatic colorimetric as-
says.	All	blood	sample	analysis	and	diagnostic	assays	were	provided	
by an accredited clinical laboratory. Cardiovascular risk was calculated 
using QRISK2, a validated prediction algorithm based on the metabolic 
indices	above,	BMI,	age,	blood	pressure	and	socioeconomic	indicators,	
to estimate the percentage risk of a cardiovascular event within the 
next	10	years	(Collins	&	Altman,	2010).	Body	composition	was	meas-
ured	with	bioelectrical	impedance	analysis	(BIA)	as	measured	with	the	
BodyStat 1500 with spot electrodes placed on the hands and feet and 
analysis conducted of % body fat (Gonzalez et al., 2018).
2.5  |  Grip strength and sit to stand test
Grip strength was selected as a measure of upper body strength, 
with participants being asked to complete three squeezes of a dy-
namometer per hand for five seconds and with scores being aver-
aged.	A	30-	second	chair	sit-	to-	stand	time	was	selected	as	a	measure	
of lower body muscle strength (Jones et al., 1999). Participants were 
asked to rise as quickly as possible to a full standing position and 
return to full sitting position as many times as possible within 30 sec-
onds, while keeping arms folded across their chest.
2.6  |  Cardiopulmonary fitness
The cardiopulmonary exercise test (CPET) is a continuous, incre-
mental exercise test to volitional exhaustion, carried out on an 
electronic cycle ergometer. CPET provides a direct measurement of 
aerobic capacity and peak oxygen consumption (V02Peak) that is re-
flective of aerobic physical fitness (Scott et al., 2015). CPET is a gold 
standard assessment for evaluating pre- operative cardiopulmonary 
fitness (Smith et al., 2009). CPET has been evaluated for reliability 
and validity in men prior to surgery for PCa (Scott et al., 2015).




tion or until a plateau in oxygen consumption as observed. Heart rate 
(HR) and volume of oxygen (V02) consumed during exercise (ml/kg/
min) were measured. Peak oxygen consumption (V02Peak) was calcu-
lated as the consecutive 20 second period of gas exchange data in the 
last	minute	before	volitional	exhaustion	(Nusair,	2017).	Men	were	not	
included in the CPET analysis if they were unable to reach V02 Peak 
or if the CPET test was stopped for safety reasons.
All	results	from	the	physical	fitness	assessments	were	compared	
with	 population	 norms	 (Aspenes	 et	 al.,	 2011;	 Massy-	Westropp	
et al., 2011; Reuter et al., 2011; Strassmann et al., 2013), before 
being classified against age- matched normative values into low 
(below the age- specific norm), moderate (within age norms) or high 
(above age norms).




F I G U R E  1 Strobe	diagram	of	sample	
and data collection
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used for normally distributed variables, median and interquartile 
range for non- normally distributed variables and count and per-
centage	for	categorical	variables.	ANOVA	was	used	to	test	for	dif-
ferences between the age groups. Univariate analysis was used to 
explore demographic and treatment factors that could be associated 
with	 cardiopulmonary	 fitness.	Multivariate	 analysis	 with	 stepwise	
linear regression and backward elimination was used to investigate 
strength of association of factors with cardiopulmonary fitness 
(CPET V02 Peak). Data were imputed using a multiple imputation 
method with 5 data sets. The results presented for univariate and 
multivariate regression analyses are based on pooled results from 





n = 22 (26.5%)
65– 75 n = 47 
(56.6%)
>75 years 
n = 14 (16.8%)
Cancer centre
Centre 1 n (%) 62 (74.7) 15 (68.2) 37 (78.7) 10 (71.4)
Centre 2 n (%) 21 (25.3) 7 (31.8) 10 (21.3) 4 (28.6)
Age	(Years)
Mean	(SD) 68.2 (7.4) 58.6 (4.4) 69.5 (2.9) 78.7 (2.0)
Ethnicity n (%)
Caucasian 80 (96.4) 20 (90.9) 46 (97.9) 14 (100.0)
Black British 3 (3.6) 2 (9.1) 1 (2.1) 0 (0.0)
Retired n (%)
Yes 19 (22.9) 8 (36.4) 11 (23.4) 0 (0.0)
No 54 (65.1) 8 (36.4) 35 (74.5) 11 (78.6)
Missing 10 (12) 6 (27.3) 1 (2.1) 3 (21.4)
Treatment (men had combined treatments)
Surgery 53 (63.9) 17 (77.3) 33 (72.2) 3 (21.4)
Radiotherapy 26 (31.3) 4 (18.2) 12 (25.5) 10 (71.4)
Brachytherapy 3 (3.6) 0 (0.0) 3 (0.0) 0 (0.0)
Adjuvant	ADT 32 (38.6) 6 (27.3) 15 (31.9) 11 (78.6)
ADT<6	months 7 (8.4) 0 (0) 3 (3.6) 4 (4.8)
ADT>24	months 25 (30.1) 6 (7.2) 5 (6.0) 7 (8.4)
Time from treatment (years)
Median	(IQR) 0.8 (1.0) 0.8 (0.8) 0.8 (1.0) 0.3 (0.9)
Charlson co- morbidity index CCI (IQR)
Median	(IQR) 6 (3) 5 (3) 6 (1) 8 (3)
Diabetes 7 (8.4) 1 (4.5) 2 (4.2) 4 (28.6)
Statins 14 (16.8) 2 (2.4) 11 (13.2) 1 (1.2)
Smoking status N (%)
Non- smoker 45 (54.2) 13 (59.1) 27 (57.4) 5 (35.7)
Ex- smoker 27 (32.5) 5 (22.7) 18 (38.3) 4 (28.6)
Current smoker 4 (4.8) 2 (9.1) 1 (2.1) 1 (7.1)
Missing 7 (8.4) 2 (9.1) 1 (2.1) 4 (28.6)
Body	Mass	Index	
(BMI)	Kg/m2a 
28.9 (SD3.4) 29.8(4.1) 28.5(3.2) 29.1(2.8)
Normal 5 (6.0) 3 (13.6) 2 (4.2) 0 (0.0)
Overweight 53 (63.9) 10 (45.5) 34 (72.3) 9 (64.3)






26.3 (22.7) 40.7 (31.0) 23.7(19.3) 16 (11.2)
aBMI	categorisation	for	men:	Normal	18.5–	24.9	Overweight	25–	29.9	Obese	>30.
TA B L E  1 Demographic	and	treatment	
characteristics across age groups for men 
with prostate cancer
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using complete cases and this yielded the same results (sensitivity 
analysis). Statistical significance was considered at 0.05 level. Data 
were	 entered	 checked	 for	 quality	 and	managed	 in	 Excel.	 All	 data	
pre- processing and statistical analyses were performed in R statisti-




A	 total	 of	 83	men	participated	 in	 the	 study	 at	 the	 two	 centres	 in	
the UK (Surrey and Newcastle), their characteristics are presented in 
Table 1. Data are presented across three age groups men <65 years 
of	 age	 (n	 =	 22,	 26.5%),	 65-	75y	 (n	 =	 47,	 56.6%)	 and	 >75y	 (n	 =	 14,	
16.8%).	 The	mean	 age	 of	men	was	 68.2	 ±	 7.4	 y.	Most	men	were	
Caucasian (96.4%) and still in employment (65.1%). The majority of 
men	were	treated	with	surgery	(63.9%),	radiotherapy	(31.3%)	or	ADT	
either	as	an	adjuvant	or	standalone	 (38.6%).	Most	of	 the	men	 (25,	
30.1%)	were	on	ADT	for	24	months	with	7	 (8.4%)	receiving	short-	
course	 ADT	 (<6	 months).	 The	 majority	 of	 men	 had	 comorbidities	
with a median CCI of 6 (IQR 3). Type II diabetes was present in 7 
(8.4%)	men,	4	of	which	were	in	the	>75	age	group.	Statins	(HMG-	CoA	
reductase inhibitors) were taken by 14 (16.8%) of the men for lipid 
modification	of	which	only	1	was	 in	the	>75	age	group.	Most	men	
were non- smokers (54.2%) with only 4 (4.8%) active smokers and 
the remaining men having quitted smoking. On average men were 
overweight	with	a	mean	BMI	of	28.9	Kg/m2± 3.4, with no significant 
differences	between	age	groups.	Men	had	low	overall	levels	of	per-
ceived physical activity as recorded by GLTEQ.
Central obesity was a consistent finding across age groups 
(p = 0.653, Table 2), with the overall mean waist- to- hip ratio of 
0.97 ± 0.06 with 72 (86.7%) men at or above the recommended 
NHS 0.9 ratio for good health for men, and a higher proportion in 
men	>75	years	group.	The	percentage	body	fat	was	29.4	±	3.8,	with	
men	of	>75	years	having	significantly	more	 fat	 than	 the	other	age	
groups (mean of 31.7 ± 4.2) (p = 0.026). Total serum cholesterol (TC) 
(4.8 mmol/L ± 0.4), HDL- cholesterol (1.4 mmol/L, ±0.4) and the TC/
HDL ratio (3.6) were similar and within reference ranges across age 
groups.
Men	who	were	>75	years	and	with	a	higher	BMI	and	lower	phys-
ical activity levels, in the multivariate analysis were more likely to 
have poorer cardiopulmonary fitness (p < 0.001). Factors such as 
ADT,	when	compared	with	other	factors,	were	not	associated	with	
poorer cardiopulmonary fitness (Table 3).
Men	 <65	 years	 had	 lower	 mean	 risk	 of	 cardiovascular	 events	
(12 ± 8.5), which was significantly higher for men who were 
>75	years	(36.9	±	6.1)(p	<	0.001).	A	QRisk2	of	>10%	in	an	individual	
would be considered a clinical indicator for further formal assess-
ment and medical intervention, and such scores are suggestive that 
TA B L E  2 Clinical	assessment	data	characterised	by	men's	age	and	grouped	into	subcategories	<65,	65–	75,	>75.	Expressed	as	mean	(SD)	
unless otherwise specified (significance defined as p < 0.05)
Age subgroups All (n = 83)
<65 years
n = 22 (26.5%)
65– 75
n = 47 (56.6%)
>75 years
n = 14 (16.8%)
p (between 
age groups)
Waist/Hip	Ratio 0.97 (0.06) 0.96 (0.08) 0.97 (0.05) 0.97 (0.05) 0.653
Waist/Hip	ratio	≥0.9
N (%)
72 (86.7) 16 (72.7) 42 (89.3) 14 (100) 0.046
Body composition (% body fat) 29.4 (3.8) 27.0 (3.8) 29.9 (3.2) 31.7(4.2) 0.026
HbA1c	mmol/mol 41.0 (8.3) 40.2 (11.2) 39.7 (5.5) 46.1 (9.3) 0.034
People	without	diabetes	HbA1c	mmol/mol 39.2 (5.3) 38.2 (6.4) 39.0 (4.5) 42.5 (5.5) 0.099
Total serum cholesterol (TC) (mmol/l) 4.8 (0.9) 4.7 (0.7) 4.6 (0.7) 4.8 (0.9) 0.282
HDL- cholesterol (mmol/l) 1.4 (0.4) 1.3 (0.3) 1.4 (0.4) 1.4 (0.2) 0.514
TC: HDL ratio 3.6 (1.0) 4.0 (1.3) 3.5 (0.9) 3.6 (0.8) 0.625
Serum triglycerides (mmol/l) 1.8 (0.8) 1.6 (0.5) 1.8 (0.8) 2.4 (1.1) 0.034
CPET Peak VO2 (ml/kg/min) (n = 78)
a  20.7 (6.3) 24.9 (7.8) 20.3 (5.1) 15.8 (3.8) <0.001
Grip strength (kg) 38.4 (8.4) 42.3 (5.6) 39.5 (8.2) 28.6 (5.2) <0.001
Chair Sit- to- Stand 13.6 (4.1) 14.8 (4.5) 13.7 (3.9) 11.2 (2.9) 0.036
Systolic blood pressure (mm Hg) 135.7 (15.3) 136.1 (18.6) 133.8 (12.5) 141.6 (17.8) 0.240
Diastolic blood pressure (mm Hg) 81.4 (10) 87.8 (9.6) 80.1 (9.2) 77.1 (10.2) 0.005




5.0; LDL below 3.(refs).
Waist-	to-	hip	ratio	<0.9	for	men	is	considered	healthy	(refs).
aThose men able to reach V02 peak and complete CPET assessment.










Age	(years) −0.40 0.08 <0.001 −0.57 −0.24
Ethnicity (Black British) −4.18 3.65 0.256 −11.46 3.09
Retired (yes) 2.37 1.56 0.133 −0.74 5.49
Diabetes (yes) −4.52 2.42 0.066 −9.34 0.31
Charlson comorbidity 
score
−0.95 0.32 0.004 −1.59 −0.31
BMI	Kg/m2 −0.78 0.20 <0.001 −1.17 −0.38
Smoking status 
(Ex- smoker)
−1.93 1.47 0.190 −4.86 1.01
Smoking status (Current 
smoker)
−0.41 3.23 0.899 −6.86 6.03
GLTEQ score 0.11 0.03 0.001 0.04 0.17
ADT	(yes) −3.40 1.38 0.016 −6.15 −0.65
Surgery (yes) 3.21 1.41 0.025 0.41 6.01
Radiotherapy including 
brachy (yes)
−3.13 1.42 0.030 −5.95 −0.30
Time from treatment 
(years)
1.09 0.99 0.276 −0.89 3.07
Waist-	to-	hip	ratio −24.33 12.36 0.054 −49.10 0.45
Body composition, fat % −0.74 0.16 <0.001 −1.06 −0.42
Multivariate	model
Age	(years) −0.37 0.11 0.002 −0.59 −0.15
Ethnicity (Black British) −6.21 3.12 0.051 −12.45 0.04
Retired (yes) −0.24 1.40 0.865 −3.03 2.55
Diabetes (yes) −0.47 2.11 0.824 −4.71 3.76
Charlson comorbidity 
score
0.19 0.38 0.625 −0.58 0.95
BMI	Kg/m2 −0.73 0.23 0.002 −1.18 −0.27
Smoking status 
(Ex- smoker)
−1.41 1.19 0.241 −3.79 0.97
Smoking status (Current 
smoker)
0.13 2.65 0.962 −5.21 5.47
GLTEQ score 0.05 0.03 0.069 0.00 0.11
ADT	(yes) −2.06 1.78 0.254 −5.64 1.52
Surgery (yes) −0.45 1.86 0.812 −4.21 3.32
Radiotherapy including 
brachy (yes)
−0.11 1.78 0.953 −3.74 3.53
Time from treatment 
(years)
−0.12 1.05 0.914 −2.31 2.08
Waist-	to-	hip	ratio 4.28 11.43 0.710 −18.71 27.27
Body composition, fat % −0.18 0.20 0.369 −0.59 0.22
Final model with backward elimination
Age	(years) −0.36 0.07 <0.001 −0.50 −0.21
BMI	Kg/m2 −0.81 0.16 <0.001 −1.14 −0.48
GLTEQ score 0.07 0.03 0.010 0.02 0.12
Abbreviations:	ADT,	androgen	deprivation	therapy;	BMI,	body	mass	index;	GLTEQ,	Godin	leisure-	
time exercise questionnaire.
TA B L E  3 Univariate	and	multivariate	
linear	regressions.	A	final	model	obtained	
with stepwise linear regression and 
backward elimination using p- value of 
0.05 as cut- off. Investigating factors that 
are associated with cardiopulmonary 
fitness VO2 Peak as measured by the 
cardiopulmonary exercise test (CPET). 
Final equation CPET_VO2_Peak = 66.70 
–	0.36	×	Age	(years)	–	0.81	×	BMI	
+0.07 × GLTEQ score
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older men were at much higher risk of future cardiovascular events 
(NICE, 2014). There was no difference between the proportion of 
men	in	this	sample	with	QRisk2	scores	above	>20%	risk	of	10	year	
CVD, and a normal, aged- matched sample of men taken from across 
the	UK	(Collins	&	Altman,	2012)(Graph	1.)
Cardiopulmonary fitness (V02 Peak) was significantly lower 
for	 men	 who	 were	 >75	 years	 in	 comparison	 with	 men	 <65	 years	
(15.8 ± 3.8 versus 24.9 ± 7.8 ml/kg/min; p < 0.001). Grip strength 
was also higher for men under 65 years, who had a mean score 
of	42.3	±	5.6	kg	compared	with	28.6	±	5.2	kg	for	those	>75	years	
(p < 0.001). Sit to stand scores were similar across age ranges, with 
a mean of 14.8 ± 4.5 for men <65 years, compared with a mean of 
11.2	±	2.9	 for	men	who	were	>75	years	 (Table	2).	Compared	with	
normative scores, 70% (14) of men in <65 years, 41.3% in the 65– 
75	 age	 group	 and	 53.8%	 in	 the	 >75-	year	 group	 had	 grip	 strength	
classified as low and below age- specific normative values (Graph 2). 
Classifications followed a similar pattern with the sit- to- stand test, 
with 65%, 52.2% and 53.8% classified as being in the low group 
(below age normative values) for men in the <65 years, 65– 75 years 
and	>75	years	group,	respectively	(Graph	3).
4  |  DISCUSSION
The aim of this study was to compare the fitness and CVD risk 
of	 older	 and	 younger	 PCA	 patients.	 Compared	 with	 younger	
men	<75	years,	men	>75	years	with	PCa	had	greater	variability	 in	
the measures of physical fitness, metabolic health and obesity. 
Although	 ADT	 was	 more	 frequently	 prescribed	 for	 those	 men	
>75	years,	ADT	was	not	found	to	be	associated	with	cardiopulmo-
nary	fitness,	but	BMI	and	low	levels	of	physical	activity	were.	This	
study contributes to the evidence for inclusion of lifestyle inter-
ventions	and	secondary	prevention	for	men	>75	years	with	PCa	in	
clinical practice to reduce comorbidities and reverse metabolic and 
physical fitness declines.
Obesity and low levels of physical activity were associated with 
men's	poor	level	of	cardiopulmonary	fitness.	Many	of	the	men	were	
overweight	(BMI	25–	29.9	kg/m2) and had an increased waist- to- hip 
ratio	(>0.9),	indicating	central	adiposity.	Studies	suggest	that	obesity	
after	PCa	 is	 associated	with	higher	PCa	 specific	mortality	 (PCSM)	
in men with locally advanced disease (Bonn et al., 2014; Efstathiou 
et al., 2007; Vidal et al., 2017). In a recent analysis of deaths in men 
after PCa, Troeschel et al., (2020) found that post- diagnosis obesity 
(BMI	>30 kg/m2) was a risk factor for PCa recurrence. Compared 
with men having a healthy weight, men who were obese had a 29% 
(95%	CI	0.96	to	1.67)	increased	risk	of	PCSM	and	a	23%	(95%	CI1.11	
to 1.35) increased risk of mortality from all- causes. Post- diagnosis 
weight	gain	(>5%	of	body	weight)	was	also	associated	with	a	higher	
risk	 of	 PCSM,	 similar	 to	 that	 found	 in	 other	 studies	 (Bonn	 et	 al.,	
2014).	Many	of	the	men	in	our	study	had	central	adiposity,	as	mea-
sured	by	waist-	to-	hip	 ratio,	and	with	 levels	of	HbA1c	 indicative	of	
pre- diabetes, all of which could have contributed to metabolic health 
risks	 associated	with	 their	 PCa	 (Shlomai	 et	 al.,	 2016).	While	ADT-	
related cardiometabolic risk shares several of the components of 
metabolic	 syndrome	 (Di	 Sebastiano	et	 al.,	 2018),	ADT	adverse	 ef-
fects are distinct in that it develops more rapidly and is characterised 
by an accumulation of subcutaneous adipose tissue and sarcopenia 
(Turner et al., 2017). This impacts on men's body composition which 
is characterised by a loss of skeletal muscle and accumulation of 
body	fat	(Morote	et	al.,	2015).
Exercise and dietary strategies to reduce sarcopenic obesity in 
metabolic syndrome have been identified but few look at these in 
combination	(Trouwborst	et	al.,	2018).	A	systematic	review	of	cur-
rent	nutritional	strategies	for	cardiometabolic	complications	of	ADT	
identified that existing evidence for the beneficial role of diet in the 
prevention	of	ADT-	related	cardiometabolic	risk	was	limited	(Turner	
et al., 2017). Thus, strategies to reduce obesity in men following 
PCa treatment are clearly needed. However, we know little about 
the amount of weight loss that is required to elicit improvements in 
cancer	outcomes	or	how	ADT-	related	effects	on	body	weight	may	
contribute to this (Turner et al., 2017).
Predicted cardiovascular risk was elevated in our sample, with 
those in the 65– 75 age group having risk scores that would reflect 
the need for formal assessment and lifestyle intervention, and those 
in	 the	>75-	year	group	 in	 a	 range	needing	medical	 assessment	 and	
secondary prevention (NICE, 2014). Out of the sample, 14 (16.8%) of 
the	men	were	prescribed	statins	with	only	1	of	the	men	>75	years.	
Elevated	blood	pressure,	multiple	comorbidities	and	raised	BMI	all	
contributed to the prediction of 10- year risk of a cardiovascular 
event.	A	recent	registry	study	of	20,216	PCa	survivors	recorded	a	
30%	increased	risk	of	cardiovascular	events	in	men	on	ADT	(adjusted	
HR = 1.3, 95%CI = 1.2,1.4), especially in those on GnRH agonists 
and Degarilix (adjusted HR = 1.5 95% CI = 1.2,1.9)(Cardwell et al., 
2020). These results are of importance because the incidence of 
ADT-	induced	 cardiovascular	 mortality	 has	 been	 shown	 to	 be	 sig-
nificantly higher in men with pre- existing CVD (Gupta et al., 2018; 
Hu	et	 al.,	 2020).	Age	was	 also	 shown	 to	be	 a	 significant	 factor	 in	
increasing CVD risk in those without cancer, but men who had pro-
longed	use	of	ADT	(more	than	2	years)	were	found	to	have	increased	
CVD at age 74 years (OR 1.9, 95% CI 1.0– 3.5) and men with comor-
bidities had even greater CVD (OR 8.1,95% CI4.3– 15.5) than men 
G R A P H  1 QRisk	2	and	percentage	of	patients	above	>20%	
QRisk compared to reference population
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without	comorbidities	(Morgans	et	al.,	2015).	In	our	study,	elevated	
cardiovascular risks may have existed prior to the diagnosis of PCa, 
as shown in the comparison of QRisk2 data for our sample and that 
of	the	UK	(Graph	1).	As	a	tool,	this	metric	may	underestimate	CVD	
risk in men with PCa due to the increased cardiometabolic complica-
tions	of	ADT,	which	are	not	taken	into	account	in	the	QRisk2	score.	
Despite this limitation, QRisk2 could be a useful tool in urology clin-
ics	for	reviewing	pre-	existing	CVD	risk	factors	before	starting	ADT.
Decline in skeletal muscle mass and function is a common 
problem in older cancer patients which can negatively affect phys-
ical function and cancer outcomes (Handforth et al., 2014; Owen 
et	al.,	2019;	Williams	et	al.,	2020).	The	significant	difference	be-
tween mean grip strength declined as a result of increasing age, 
when compared with normative data, 70% of the scores for men 
<65 years were below age- matched norms, compared to 53% in 
the	 >75	 years	 group.	 Furthermore,	 over	 50%	 of	 men	 in	 all	 sub-
groups were below age- matched norms for lower body muscle 
strength, as evidenced by scores from the sit- to- stand test. This 
difference may reflect our measurement techniques, for example 
using leg extension and vertical bench press tests would have pro-
vided greater precision. In a recent longitudinal study of men aged 
70	to	88	years	with	PCa,	it	was	found	that	prior	to	adjuvant	ADT	
and radiotherapy, there was a high prevalence of skeletal muscle 
disorders (Couderc et al., 2020). This study highlighted the need 
for	better	assessment	of	skeletal	muscle	prior	to	ADT,	and	imple-
mentation of appropriate exercise and nutrition interventions. 
Additionally,	skeletal	muscle	loss	has	also	been	found	to	increase	
in	prolonged	use	of	ADT	which	 impacts	on	physical	fitness	up	to	
3 years after treatment (Smith et al., 2012) but was not associated 
in our study with cardiopulmonary fitness. Resistance training and 
other	 forms	of	physical	activity	during	ADT	have	been	shown	to	
reduce body fat, maintain skeletal muscle mass and insulin sensi-
tivity	(Winters-	Stone	et	al.,	2015).	Exercise	has	also	been	shown	to	
ameliorate	 a	 range	of	ADT-	related	 side	effects,	 including	 fatigue	
and	 impaired	health-	related	quality	of	 life	 (Cormie	&	Zopf,	2018)	
and can improve cardiovascular risk profile (Ndjavera et al., 2020). 





younger age groups. The large discrepancy between the average 
peak VO2	 value	 recorded	 for	 PCa	 patients	 >75	 years	 and	 those	
<65 years was notable. However, the results are even more alarming 
when compared with age- matched norms. Normative data for V02 
peak	oxygen	uptake	reported	by	Aspenes	et al.	(Aspenes	et	al.,	2011)	
show that the average values for older PCa patients in the present 
study	were	only	52%	of	those	for	the	most	inactive	men	>70	years.	
Furthermore, PCa patients in the <65 years age group only achieved 
an average score that was 72% of that for the most inactive men 
in the age range of 60– 69 years. This suggests there is an urgent 
need for exercise interventions aimed at improving aerobic fitness 
in PCa patients of all ages but particularly for older patients. In a 
review of 27 RCTs, including a meta- analysis of 19 pooled studies 
on physical activity in cancer survivors, Grimmett et al. (Grimmett 
et al., 2019) found that existing data suggest that exercise interven-
tions are effective in achieving only modest increases in physical 
activity at least 3 months post- intervention. Furthermore, exercise 
interventions were less likely to be effective in older cancer survi-
vors, who would gain benefit from the provision of greater support, 
particularly those with physical limitations who are less likely to en-
gage	in	exercise	(Weller	et	al.,	2019).	However,	initiating	exercise	and	
nutritional interventions prior to PCa treatment via prehabilitation 
(Faithfull et al., 2019) may be more effective than providing inter-
ventions after cancer treatment when metabolic and cardiovascular 
changes have already occurred.
A	potential	study	limitation	we	encountered	was	that	we	invited	
men into the study who were identified as having pre- existing risk 
G R A P H  2 Upper	body	strength	as	measured	by	grip	
strength compared to age- specific norms based on data from 
(Massy-	Westropp	et	al.,	2011)
G R A P H  3 Lower	body	strength	across	age	groups	compared	
to age- specific norms based on data from Strassmans study 
(Strassmann et al., 2013)
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factor	for	CVD,	such	as	elevated	BP,	BMI>25kg/m2 and/or receiving 
ADT.	Our	sample	may	therefore	not	reflect	the	wider	PCa	popula-
tion.	We	were	also	not	able	to	compare	our	data	against	a	non-	PCa	
population of men using our methodology but relied on normative 
values generated in prior studies, future work would benefit from 
having normative controls. Despite this limitation, our study draws 
attention to the missed opportunities for health promotion in men 
with	PCa.	Large	scale	studies	demonstrate	that	men	with	PCA	are	
at greater risk for incident cardiovascular disease (Troeschel et al., 
2020), diabetes mellitus (Zaorsky et al., 2017), osteoporosis and 
functional	decline	 (Winters-	Stone	et	 al.,	 2017).	Our	 study	 reflects	
the need to address how the adverse effects of treatment are super-
imposed on existing levels of co- morbidity and identifies those most 
in need of assessment and secondary prevention.
5  |  CONCLUSION
We	 found	 that	men	with	 PCa	 >75	 years	 had	more	 cardiovascular	
risk factors, poorer physical function and lower strength compared 
to normative standards for men of their age. Fitness parameters 
were worse in older men with PCa than younger patients but to a 
far greater extent than in normal ageing, thereby raising the pro-
file of the importance of lifestyle interventions in this population. 
This study indicates the need for proper individualised assessment 
of	fitness	parameters	in	men	who	are	>75	years	for	an	exercise	and	
dietary prescription. Opportunities to integrate secondary preven-
tion as part of PCa treatment are also important for ameliorating the 
long- term health consequences of PCa and its treatments.
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